The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody.
Immunogen design for HIV-1 vaccines could be based on epitope identification of naturally occurring neutralizing antibodies in infected patients. A tier 2 neutralizing monoclonal antibody (mAb), HJ16 recognizes a new epitope in the CD4 binding site (CD4bs) region that only partially overlaps with th...
Guardado en:
Autores principales: | Sunita S Balla-Jhagjhoorsingh, Davide Corti, Leo Heyndrickx, Elisabeth Willems, Katleen Vereecken, David Davis, Guido Vanham |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7f92aeb3878d4fa3843e47aaabbfeeb0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Global site-specific N-glycosylation analysis of HIV envelope glycoprotein
por: Liwei Cao, et al.
Publicado: (2017) -
Alterations in protein expression and site-specific N-glycosylation of prostate cancer tissues
por: Simon Sugár, et al.
Publicado: (2021) -
Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies
por: Christopher A. Cottrell, et al.
Publicado: (2021) -
Site-specific N-glycosylation analysis of animal cell culture-derived Zika virus proteins
por: Alexander Pralow, et al.
Publicado: (2021) -
Acta Nº276
por: Banco Central de Chile
Publicado: (2019)